Nex Eye is a Pharmaceutical startup that was founded in 2021. The company recently secured a significant KRW22.00B Series A investment on 25 October 2022. The round was backed by a diverse group of investors including DSC Investment, CJ Investment, GC Pharma, Stone Bridge Ventures, Schmidt, Medytox Venture Investment, TS Investment, Hana Ventures, WONIK Investment Partners, and Atinum Partners.
This funding demonstrates a strong show of support and confidence from a notable group of investors in Nex Eye's potential within the pharmaceutical industry. The investment not only provides Nex Eye with substantial capital to further develop its capabilities and grow its operations, but also represents a validation of the company's business model and strategic direction. With this infusion of funds and the backing of these prominent investors, Nex Eye is well-positioned to make a significant impact within the pharmaceutical sector.
Nex Eye
Founded 2021
Series A
Total: $26.00B
Pharmaceutical
General Information
Company Name
Nex Eye
Founded Year
2021
Industries
Pharmaceutical
Funding Stage
Series A
BounceWatch is an independent company data service, not affiliated with Nex Eye. To contact Nex Eye, visit nex-i.co.kr.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
Pharmaceutical
About Nex Eye
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | KRW22.00B | 10 |
|
25 Oct 2022 |
| Seed Round | KRW4.00B | - |
|
22 Dec 2021 |
FAQ About Nex Eye
Nex Eye was founded in 2021.
Nex Eye operates in Pharmaceutical.
Nex Eye has completed 2 funding rounds, raising a total of $26.00B. The latest funding stage is Series A.
We're actively collecting intelligence on Nex Eye.
Source: BounceWatch company record for Nex Eye, https://bouncewatch.com/company/nex-eye, updated 12 September 2024. When citing, please name BounceWatch and link this page.
